SAS joins Rapidly Emerging Antiviral Drug Development Initiative to advance drug discovery with artificial intelligence and machine learning.
SAS, a leader in analytics and software services, and the University of North Carolina at Chapel Hill are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19.
The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI) which is developing broad-spectrum antiviral drugs to have on the shelf to prevent future pandemics
To advance their work, SAS research and development teams are applying advanced machine learning techniques to integrate multiple biological data sets from the deep lung environment of severely ill COVID-19 patients. These analyses will be used by Carolina researchers to identify targets for new COVID-19 antiviral drugs.
“SAS strives to create a healthier world through analytics,” said SAS Chief Executive Officer Jim Goodnight. “SAS has been the gold standard for clinical trial submission for decades, providing the data analysis for medicines that have helped countless patients. We look forward to working with READDI to deploy our most advanced technologies to accelerate drug discovery and support global health efforts to get ahead of the next pandemic.”
Read the full article here.
Comments are closed.
READDI is led by The University of North Carolina at Chapel Hill.